NYSE:GKOSMedical Equipment
Glaukos (GKOS) Could Be 2% Overvalued After Its 2026 Sales Guidance Lift
Glaukos (GKOS) is back in focus after the company raised its 2026 net sales guidance to a range of $680 million to $700 million, up from $620 million to $635 million previously.
See our latest analysis for Glaukos.
Glaukos has seen strong momentum build around these updates, with a 1-month share price return of 20.58% and a year to date share price return of 52.20%, while the 1-year total shareholder return is 95.75%.
If you are looking for more stocks connected to medical technology and eye...